Abstract
Original language | English |
---|---|
Article number | 133 |
Journal | NPJ digital medicine |
Volume | 5 |
Issue number | 1 |
DOIs | |
Publication status | Published - 1 Dec 2022 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: NPJ digital medicine, Vol. 5, No. 1, 133, 01.12.2022.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Lessons learned from recruiting into a longitudinal remote measurement study in major depressive disorder
AU - Oetzmann, Carolin
AU - White, Katie M.
AU - Ivan, Alina
AU - Julie, Jessica
AU - Leightley, Daniel
AU - Lavelle, Grace
AU - Lamers, Femke
AU - Siddi, Sara
AU - Annas, Peter
AU - Garcia, Sara Arranz
AU - Haro, Josep Maria
AU - Mohr, David C.
AU - Penninx, Brenda W. J. H.
AU - Simblett, Sara K.
AU - Wykes, Til
AU - Narayan, Vaibhav A.
AU - Hotopf, Matthew
AU - RADAR-CNS Consortium
AU - Matcham, Faith
N1 - Funding Information: We thank our colleagues both within the RADAR-CNS consortium and across all involved institutions for their contribution the recruitment strategy for RADAR-MDD. Furthermore, we would like to thank the FAST-R group, a team with experience of mental health problems and their carers who have been specially trained to advise on research proposals and documentation through the Feasibility and Acceptability Support Team for Researchers (FAST-R): a free, confidential service in England provided by the National Institute for Health Research Maudsley Biomedical Research Centre via King’s College London and South London and Maudsley NHS Foundation Trust. We would also like to thank all members of the RADAR-CNS patient advisory board, who all have experience of living with or supporting those who are living with depression, epilepsy or multiple sclerosis. Finally, the RADAR-CNS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA ( www.imi.europa.eu ). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body has not been involved in the design of the study, the collection or analysis of data, or the interpretation of data. This paper represents an independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Funding Information: M.H. is the principal investigator of the RADAR-CNS programme, a precompetitive public–private partnership funded by the Innovative Medicines Initiative and the European Federation of Pharmaceutical Industries and Associations. The programme receives support from Janssen, Biogen, MSD, UCB and Lundbeck. D.C.M. has accepted honoraria and consulting fees from Apple, Inc., Otsuka Pharmaceuticals, Pear Therapeutics, and the One Mind Foundation, royalties from Oxford Press, and has an ownership interest in Adaptive Health, Inc. P.A. is employed by the pharmaceutical company H. Lundbeck A/S. V.N. is an employee of Janssen Research & Development, LLC and hold company stocks/stock options. C.O. is supported by the UK Medical Research Council (MR/N013700/1) and King’s College London member of the MRC Doctoral Training Partnership in Biomedical Sciences. All other authors declare no competing interests. Funding Information: We thank our colleagues both within the RADAR-CNS consortium and across all involved institutions for their contribution the recruitment strategy for RADAR-MDD. Furthermore, we would like to thank the FAST-R group, a team with experience of mental health problems and their carers who have been specially trained to advise on research proposals and documentation through the Feasibility and Acceptability Support Team for Researchers (FAST-R): a free, confidential service in England provided by the National Institute for Health Research Maudsley Biomedical Research Centre via King’s College London and South London and Maudsley NHS Foundation Trust. We would also like to thank all members of the RADAR-CNS patient advisory board, who all have experience of living with or supporting those who are living with depression, epilepsy or multiple sclerosis. Finally, the RADAR-CNS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body has not been involved in the design of the study, the collection or analysis of data, or the interpretation of data. This paper represents an independent research part funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Publisher Copyright: © 2022, The Author(s).
PY - 2022/12/1
Y1 - 2022/12/1
N2 - The use of remote measurement technologies (RMTs) across mobile health (mHealth) studies is becoming popular, given their potential for providing rich data on symptom change and indicators of future state in recurrent conditions such as major depressive disorder (MDD). Understanding recruitment into RMT research is fundamental for improving historically small sample sizes, reducing loss of statistical power, and ultimately producing results worthy of clinical implementation. There is a need for the standardisation of best practices for successful recruitment into RMT research. The current paper reviews lessons learned from recruitment into the Remote Assessment of Disease and Relapse- Major Depressive Disorder (RADAR-MDD) study, a large-scale, multi-site prospective cohort study using RMT to explore the clinical course of people with depression across the UK, the Netherlands, and Spain. More specifically, the paper reflects on key experiences from the UK site and consolidates these into four key recruitment strategies, alongside a review of barriers to recruitment. Finally, the strategies and barriers outlined are combined into a model of lessons learned. This work provides a foundation for future RMT study design, recruitment and evaluation.
AB - The use of remote measurement technologies (RMTs) across mobile health (mHealth) studies is becoming popular, given their potential for providing rich data on symptom change and indicators of future state in recurrent conditions such as major depressive disorder (MDD). Understanding recruitment into RMT research is fundamental for improving historically small sample sizes, reducing loss of statistical power, and ultimately producing results worthy of clinical implementation. There is a need for the standardisation of best practices for successful recruitment into RMT research. The current paper reviews lessons learned from recruitment into the Remote Assessment of Disease and Relapse- Major Depressive Disorder (RADAR-MDD) study, a large-scale, multi-site prospective cohort study using RMT to explore the clinical course of people with depression across the UK, the Netherlands, and Spain. More specifically, the paper reflects on key experiences from the UK site and consolidates these into four key recruitment strategies, alongside a review of barriers to recruitment. Finally, the strategies and barriers outlined are combined into a model of lessons learned. This work provides a foundation for future RMT study design, recruitment and evaluation.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85137943093&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36057688
UR - http://www.scopus.com/inward/record.url?scp=85137943093&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41746-022-00680-z
DO - https://doi.org/10.1038/s41746-022-00680-z
M3 - Article
C2 - 36057688
SN - 2398-6352
VL - 5
JO - NPJ digital medicine
JF - NPJ digital medicine
IS - 1
M1 - 133
ER -